Qualigen Therapeutics, Inc..
QLGN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. Their pipeline includes preclinical and clinical-stage drug candidates targeting various oncology indications, such as pancreatic cancer and other soli...Show More
Better Health for All
20
Qualigen Therapeutics is dedicated to developing novel therapeutics for cancer and infectious diseases, focusing on areas with high unmet medical needs such as metastatic pancreatic cancer, which has a low survival rate.
1
Their lead experimental drug, QN-302, is in Phase 1 clinical trials for advanced or metastatic solid tumors.
2
Early clinical data from three pancreatic cancer patients showed no Dose Limiting Toxicity (DLTs) or Significant Adverse Events (SAEs), with two patients experiencing no disease progression.
3
The company received Orphan Drug Designation for QN-302 for Pancreatic Ductal Adenocarcinoma (PDAC) from the FDA in January 2023.
4
Qualigen conducts its clinical trials in accordance with FDA regulations.
5
However, the company does not currently offer expanded access to investigational drugs outside of clinical trials, though this policy may be reassessed.
6
Fair Money & Economic Opportunity
0
No evidence available to assess Qualigen Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
Insufficient evidence to determine a value score for Qualigen Therapeutics, Inc. regarding Fair Pay & Worker Respect. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary: Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for cancer. Their lead program, QN-302, is in Phase 1 clinical trials. The company is based in Carlsbad, California. As a research and development company, its primary activities involve laboratory work, clinical trials, and administrative functions to support these activities.
Peer Comparison: Compared to other clinical-stage biotech companies, Qualigen's impact on "Fair Pay & Worker Respect" is likely similar. Biotech companies generally require skilled researchers and lab technicians, and competition for talent often necessitates fair compensation. However, smaller companies may have less formalized policies or resources dedicated to worker welfare compared to larger pharmaceutical corporations.
Materiality Assessment: The business model is fundamentally neutral to supportive of this value, with medium materiality.
Detailed Rationale: As a company reliant on skilled labor for research and development, Qualigen has a direct interest in attracting and retaining talent through fair compensation and a positive work environment. While the company's direct impact on worker respect is primarily limited to its employees, maintaining safe laboratory conditions and adhering to labor laws are crucial. The absence of manufacturing or extensive supply chains reduces the risk of indirect labor violations. However, the company's size and stage of development may limit its capacity to implement extensive worker welfare programs compared to larger pharmaceutical companies.
Value Interaction Notes: N/A
Scoring Boundary Flags: Scores significantly below average would be illogical, as the company's success depends on attracting and retaining skilled labor through fair practices. Scores in the lowest quartile should be flagged.
Fair Trade & Ethical Sourcing
0
No relevant data was found in the provided articles to assess Qualigen Therapeutics, Inc. against the Fair Trade & Ethical Sourcing value. All articles indicated that content could not be retrieved or contained no extractable information.
1
Honest & Fair Business
0
Qualigen Therapeutics, Inc. was delisted from Nasdaq on May 5, 2025, due to the delinquent filing of its 2024 Form 10-K.
1
The company filed an appeal on May 1, 2025, to regain compliance.
2
Additionally, it received a Nasdaq deficiency notification on May 19, 2025, for failing to timely file its Quarterly Report (10-Q) for the period ended March 31, 2025.
3
A material weakness in internal control over financial reporting was identified in the 2024 audit, which led to adjustments and a late filing.
4
Kind to Animals
-60
The company uses animals for product testing, as evidenced by QN-302 showing anti-tumor activity in various animal models.
1
There is no information provided about a formal animal testing policy, its scope, or enforcement, which aligns with a vague policy or lack thereof where routine testing continues. The company's engagement with public policy is limited to QN-302 being granted Orphan Drug status and Investigational New Drug (IND) clearance by the FDA, which pertains to drug approval processes rather than animal welfare policy improvement or advocacy for higher standards.
2
No War, No Weapons
0
No evidence available to assess Qualigen Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence was found in the provided articles regarding Qualigen Therapeutics, Inc.'s environmental performance, including emissions, renewable energy use, water management, green building certifications, waste diversion, climate targets, or any other planet-friendly business practices.
Respect for Cultures & Communities
0
No evidence available to assess Qualigen Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Qualigen Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Qualigen Therapeutics, Inc. on Zero Waste & Sustainable Products.